MedTrace Logo

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

NCT07172347 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-01-02

No results posted yet for this study

Summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Conditions

  • Non-segmental Vitiligo

Interventions

DRUG

VC005 tablets

VC005 groups repeat administration for 52 weeks

DRUG

VC005 Tablets Placebo

VC005 Placebo groups repeat administration for 52 weeks

Sponsors & Collaborators

  • Jiangsu vcare pharmaceutical technology co., LTD

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2027-08-30
Completion
2027-08-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07172347 on ClinicalTrials.gov